Literature DB >> 27256097

Comparing Clinicopathologic and Radiographic Findings Between TT-UMP, Classical, and Non-Encapsulated Follicular Variants of Papillary Thyroid Carcinomas.

Husniye Baser1, Oya Topaloglu2, Abbas Ali Tam2, Afra Alkan3, Aydan Kilicarslan4, Reyhan Ersoy2, Bekir Cakir2.   

Abstract

Thyroid tumors of uncertain malignant potential (TT-UMP) comprise an accepted subgroup of follicular-patterned thyroid tumors for which benignancy or malignancy cannot be precisely assessed. We aimed to evaluate the demographic characteristics, ultrasound (US) findings, and cytological results of patients with TT-UMP and compare these findings to a classical variant of papillary thyroid carcinoma (CV-PTC) and non-encapsulated follicular variant of PTC (NEFV-PTC) patients; we also evaluated the immunohistochemical characteristics of patients with TT-UMP. Twenty-four patients with TT-UMP, 672 with CV-PTC, and 132 with NEFV-PTC were included in the study. Mean longitudinal nodule size and median nodule volume were higher in the TT-UMP group than in the CV-PTC and NEFV-PTC groups (p < 0.001 and p < 0.001 for CV-PTC; p < 0.001 and p = 0.008 for NEFV-PTC). The presence of halo and peripheral vascularization was observed more frequently in the TT-UMP group than in the CV-PTC group (p = 0.002 and p = 0.024). Benign and follicular neoplasm/suspicious for follicular neoplasm cytological results were higher in the TT-UMP group than in the CV-PTC group (p = 0.030 and p = 0.001). US findings were similar between TT-UMP and NEFV-PTC groups (all, p > 0.05). However, none of the patients with TT-UMP were called malignant; 105 patients (31.2 %) of CV-PTC and 11 patients (9.5 %) of NEFV-PTC (infiltrative FV) were classified as malignant cytologically. Tumor size was higher in the TT-UMP group than in the CV-PTC and NEFV-PTC groups (p < 0.001 and p = 0.006). In the TT-UMP group, positive expression of HBME-1, CK-19, and Gal-3 was found in 50, 33.3, and 25 % of patients, respectively. This study demonstrated that none of the TT-UMP patients were evaluated as malignant in preoperative cytology. However, patients with TT-UMP had higher nodule and tumor sizes than CV-PTC and NEFV-PTC patients; US features were similar between NEFV-PTC and TT-UMP patients.

Entities:  

Keywords:  Classical variant of papillary thyroid carcinoma; Cytology; Non-encapsulated follicular variant of papillary thyroid carcinoma; Thyroid tumors of uncertain malignant potential; Ultrasound

Mesh:

Substances:

Year:  2016        PMID: 27256097     DOI: 10.1007/s12022-016-9437-4

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  48 in total

1.  New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid.

Authors:  Eun-Kyung Kim; Cheong Soo Park; Woung Youn Chung; Ki Keun Oh; Dong Ik Kim; Jong Tae Lee; Hyung Sik Yoo
Journal:  AJR Am J Roentgenol       Date:  2002-03       Impact factor: 3.959

2.  Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential: a morphological, immunohistochemical, and molecular appraisal.

Authors:  Zhiyan Liu; Gengyin Zhou; Misa Nakamura; Eisuke Koike; Yaqiong Li; Takashi Ozaki; Ichiro Mori; Emiko Taniguchi; Kennichi Kakudo
Journal:  Cancer Sci       Date:  2010-11-10       Impact factor: 6.716

3.  Follicular variant of papillary carcinoma. Cytologic and histologic correlation.

Authors:  Z W Baloch; P K Gupta; G H Yu; M J Sack; V A LiVolsi
Journal:  Am J Clin Pathol       Date:  1999-02       Impact factor: 2.493

4.  The Bethesda System for Reporting Thyroid Cytopathology.

Authors:  Edmund S Cibas; Syed Z Ali
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

5.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

6.  Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19.

Authors:  Figen Barut; Nilufer Onak Kandemir; Sibel Bektas; Burak Bahadir; Sevinc Keser; Sukru Oguz Ozdamar
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

7.  Cytological features of well-differentiated tumors of uncertain malignant potential: Indeterminate cytology and WDT-UMP.

Authors:  Keiko Nishigami; Zhiyan Liu; Emiko Taniguchi; Eisuke Koike; Takashi Ozaki; Ichiro Mori; Kennichi Kakudo
Journal:  Endocr J       Date:  2012-04-07       Impact factor: 2.349

8.  Ultrasonographic findings of papillary thyroid carcinoma with Hashimoto's thyroiditis.

Authors:  Nariko Ohmori; Megumi Miyakawa; Kazue Ohmori; Kazue Takano
Journal:  Intern Med       Date:  2007-05-01       Impact factor: 1.271

9.  Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings.

Authors:  Il Seong Nam-Goong; Ha Young Kim; Gyungyub Gong; Ho Kyu Lee; Suck Joon Hong; Won Bae Kim; Young Kee Shong
Journal:  Clin Endocrinol (Oxf)       Date:  2004-01       Impact factor: 3.478

10.  A pathologic re-review of follicular thyroid neoplasms: the impact of changing the threshold for the diagnosis of the follicular variant of papillary thyroid carcinoma.

Authors:  Sandy Widder; Kelly Guggisberg; Moosa Khalil; Janice L Pasieka
Journal:  Surgery       Date:  2008-01-30       Impact factor: 3.982

View more
  2 in total

Review 1.  Overview of the 2022 WHO Classification of Thyroid Neoplasms.

Authors:  Zubair W Baloch; Sylvia L Asa; Justine A Barletta; Ronald A Ghossein; C Christofer Juhlin; Chan Kwon Jung; Virginia A LiVolsi; Mauro G Papotti; Manuel Sobrinho-Simões; Giovanni Tallini; Ozgur Mete
Journal:  Endocr Pathol       Date:  2022-03-14       Impact factor: 3.943

2.  DNA Methylation Haplotype Block Markers Efficiently Discriminate Follicular Thyroid Carcinoma from Follicular Adenoma.

Authors:  Hui Zhang; Zhenzhen Zhang; Xiaoding Liu; Huanli Duan; Tianmin Xiang; Qiye He; Zhixi Su; Huanwen Wu; Zhiyong Liang
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.